Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

NovoLog® Mix 70/30 (Biphasic Insulin Aspart 70/30) Titrate-To-Target: An Observational Study of the Efficacy of NovoLog® Mix 70/30 in Patients With Type 2 Diabetes Mellitus Not Achieving Glycemic Targets on OADs With / Without Once Daily Basal Insulin Therapy

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the effectiveness of biphasic insulin aspart 30 in type 2 diabetics not achieving blood sugar levels when treated with oral anti-diabetics drugs (OADs) with or without basal insulin therapy.

Inclusion Criteria:

• Type 2 diabetes mellitus for at least 12 months
• HbA1c: 7.5-10.0%
• An antidiabetic regimen that has been stable for at least 3 months
• Able and willing to perform SMBG testing as per protocol

Exclusion Criteria:

• Use of any insulin preparations other than NPH or glargine within the past 6 months
• Pregnancy, breastfeeding, intention to become pregnant within the next 12 months, or judged to be using inadequate contraceptive measures (adequate contraceptive measures includes: sterilization, intrauterine devices, oral contraceptives, or consistent use of barrier methods)
• Known or suspected allergy to trial product or agents related to trial product